£40,000 Placing

Shortwave Life Sciences Plc

10 June 2025

 

SHORTWAVE LIFE SCIENCES PLC

("Shortwave" or "the Company")

10 June 2025

Shortwave Life Sciences Announces Private Placement for Corporate Purposes

£40,000 Placing at £0.00125 per share

Shortwave Life Sciences PLC (PSY), the UK's leading biopharmaceutical company focused on developing innovative treatments for anorexia nervosa, is pleased to announce the placing of 32,000,000 ordinary shares of £0.001 ("Placing Shares") at a price of £0.00125 per share ("Placing Price"), raising £40,000 ("Placing"). As part of the Placing, the Company has granted one warrant for every one new Placing Share subscribed for, exercisable at a price of £0.0015 pence per share, valid until 30 June 2027.

A further 2,560,000 warrants have been granted to an introducer, on the same terms as the placing warrants.

This funding is an interim round with use of proceeds directed at settlement of outstanding Company debt.

Admission

Application will be made for the 32,000,000 Placing Shares to be admitted to trading on the Aquis Growth Market ("Admission"). It is expected that Admission of the new ordinary shares will become effective on or around 8.00 a.m. on or around 16 June 2025. 

Total Voting Rights 

Following Admission of the Placing Shares, the Company's total number of Ordinary Shares in issue will be 410,290,762, with voting rights. The Company does not hold any Ordinary Shares in treasury. The figure of 410,290,762 Ordinary Shares may therefore be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

About Shortwave Life Sciences:

Shortwave Life Sciences is a developer of breakthrough therapies addressing unmet medical needs in mental health. The Company is committed to the advancement of innovative solutions through drug development, with a mission to pioneer breakthrough therapies that transform the landscape of mental health care. With a team of dedicated experts and a commitment to innovation, Shortwave Life Sciences is uniquely positioned to introduce and develop solutions for the complex challenges of mental health disorders worldwide.

The Directors of the Company accept responsibility for the contents of this announcement.

For media inquiries, please contact:

Enquiries:

Company:

Rivki Stern:  [phone]

Peterhouse Capital Limited:

Corporate Adviser:

+ 44 (0) 20 7469 0930

Corporate Broker:

[phone]

 

END